STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Brecken, a 12-year-old from a St. Paul suburb, began receiving Avidity Biosciences' experimental drug Del-zota last winter and is "shockingly" improving, while his online friend Yannick, 13, of San Diego — both living with Duchenne — continues to decline.
- Del-zota uses exon-skipping to make cells produce a shortened but functional version of a muscle-survival protein, and in trials the approach appeared to virtually arrest the disease in some patients.
- Avidity Biosciences' Del-zota is under FDA review but targets a single specific mutation, making only about 7% of U.S. Duchenne patients — roughly 900 Americans — eligible for the therapy.
- Exon-skipping strategies could in principle benefit about 70% of the 10,000–15,000 Duchenne boys and men in the U.S., but each drug must be matched to a patient's individual mutation.
Why it matters: With Del-zota under FDA review and only ~900 of the 10,000–15,000 U.S. Duchenne patients eligible due to mutation specificity, the approval decision will determine whether families gain access to a therapy that virtually arrested the disease in some trial patients — while the remaining ~93% wait for mutation-matched alternatives in a disease that almost exclusively kills males.
Ask SkimNews
